Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats

Oncology

Volumn 57, Issue 1, 1999, Pages 77-82

  Tsujitani, Shunichi ^a   Oka, A ^a   Kondo, A ^a   Katano, K ^a   Oka, S ^a   Saito, H ^a   Ikeguchi, M ^a   Maeta, M ^a   Kaibara, N ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Cisplatin; Hypotonic chemotherapy; Intraperitoneal chemotherapy; Peritoneal carcinomatosis

Indexed keywords

CISPLATIN; HYPOTONIC SOLUTION; ISOTONIC SOLUTION; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARCINOMATOUS PERITONITIS; DRUG BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; OSMOLARITY; PERITONEAL FLUID; PRIORITY JOURNAL; RAT; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; HYPOTONIC SOLUTIONS; INFUSIONS, PARENTERAL; MALE; OSMOLAR CONCENTRATION; PERITONEAL NEOPLASMS; RATS; TIME FACTORS;

EID: 0032988729     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012004     Document Type: Article

References (22)

1. Wilke H, Preusser P, Fink U, Achterrah W, Meyer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, Köhne-Wömpner CH, Harstrick A, Schmoll HJ: New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17:61-70.
2. Markman M: Intraperitoneal chemotherapy. Semin Oncol 1991;18:248-254.
3. Gottlieb JA, Drewinko B: Review of the current clinical status of platinum co-ordination complexes in cancer chemotherapy. Cancer Chemother Rep 1975;59:621.
4. Tsujitani S, Okuyama T, Watanabe A, Abe Y, Maehara Y, Sugimachi K: Intraperitoneal cisplatin during surgery for gastric cancer and peritoneal seeding. Anticancer Res 1993;13: 1831-1834.
5. Cunliffe WJ, Sugarbaker PH: Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 1989;76:1082-1090.
6. Los G, McVie JG: Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990;26:755-762.
7. Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVei JG: Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380-3384.
8. Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis JR JL, Barakat R, Rumin S, Mychalczak B, Saigo P, Almadrones L, Hoskins W: Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 1993;71:1565-1570.
9. Groose E, Walker L, Masters JR: The influence of osmolarity on drug cytotoxicity in vitro. Br J Cancer 1986;54:181.
10. Smith E, Brock AP: The effect of reduced osmolarity on platinum drug toxicity. Br J Cancer 1989;59:873-875.
11. Kondo A, Maeta M, Oka A, Tsujitani S, Ikeguchi M, Kaibara N: Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer 1996;73:1166-1170.
12. Whitlam JB, Brown KF: Ultrafiltration in serum protein binding determinations. J Pharm Sci 1981;70:146-150.
13. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 1977;18:184-191.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
15. Melvik JE, Dornish JM, Pettersen EO: The binding of cis-dichlorodiammineplatinum (II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. Br J Cancer 1992;66:260-265.
16. Atiq OT, Kelsen DP, Shiu MH, Salz L, Tong W, Niedzwiecki D, Trochanowski B, Lin S, Toomasi F, Brennan M: Phase II trial of post-operative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 1993;11:425-433.
17. Los G, Verdegaal EME, Mutsaers PHA, McVie JG: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991;28:159-165.
18. Rosenberg B: Anticancer activity of cis-dichlorodiammineplatinum (II) and some relevant chemistry. Cancer Treat Rep 1969;63:1433-1438.
19. Connors TA, Cleare MJ, Harrap KR: Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat Rep 1979;63:1499-1502.
20. Lum BL, Degregorio MW, Holleran WM, Daroza R, Brown M, Shiffman R, Jacobs CD, Lewis BJ, Halsey J, Scudder SA, Sikic BI: The clinical pharmacology of intraperitoneal carboplatin: A phase I/II study of the Northern California Oncology Group. Proc Am Soc Oncol 1986;5:50.
21. Stephen RL, Novak JM, Jensen EM, Kablitz C, Buys SS: Effect of osmotic pressure on uptake of chemotherapeutic agents by carcinoma cells. Cancer Res 1990;50:4704-4708.
22. Ichinose Y, Hara N, Ohta M, Asoh H, Yano T, Maeda K, Yagawa K: Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer: In vitro experiments and preliminary clinical results. J Thorac Cardiovasc Surg 1993;105: 1041-1046.